- Home
- AACG vs NSRX Comparison
AACG vs NSRX Comparison
Compare AACG & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AACG | NSRX |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.5M | 37.1M |
| IPO Year | 2008 | 2024 |
Fundamental Metrics
Financial Performance| Metric | AACG | NSRX |
|---|---|---|
| Price | $0.73 | $3.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | 17.3K | ★ 23.8K |
| Earning Date | 11-11-2026 | 08-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $1.98 |
| 52 Week High | $1.48 | $9.50 |
Technical Indicators
Market Signals| Indicator | AACG | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 49.20 |
| Support Level | $0.60 | $2.97 |
| Resistance Level | $0.97 | $3.60 |
| Average True Range (ATR) | 0.09 | 0.27 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 28.22 | 42.47 |
Price Performance
Historical ComparisonAbout AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.
About NSRX Nasus Pharma Ltd. Ordinary Shares
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.